Efficacy of Alendronate in Preventing Periprosthetic Bone Loss after Implantation of a Primary Hip Endoprosthesis

Abstract

Total hip arthroplasty (THA) is now the gold standard for the surgical treatment of coxarthrosis. The appearance of bone loss after implantation of the hip endoprosthesis over time reduces the primary stability of the implant and leads to progressive looseningof the implant, or periprosthetic fracture, which are considered to be the most common causes of hip revision.
 The aim of this study is to evaluate the value of alendronate application in reducing periprosthetic osteolysis reduction after implantation of total cementless hip endoprosthesis.
 The study analyzed 50 patients operated on with implantation of a cementless total hip arthroplasty (THA). The first group of 25 patients recieved oral alendronate, calcium and vitamin D3 postoperatively. The second group of 25 patients were examined and followed postoperatively without any therapy.
 Patients were examined by RTG and DXA methods at 6, 12 and 18 months.
 The study showed a difference in the values of bone mineral density (BMD) and bone mineral content (BMC) in the interval of 6,12 and 18 months, using the DXA method.
 Alendronate therapy after total hip implantation reduces periprosthetic bone loss, maintains bone mineralization and strengthens the implant

Nanomechanical behavior, adhesion and wear resistance of tin oxide coatings for biomedical applications

“…Indeed, in some cases where wear particles appear as a result of friction, the application of a biomaterial will be limited. In fact, they can lead to periprosthetic bone loss in the tissues surrounding the implant, causing unpleasant tissue reactions such as inflammation [6–8]. Biomaterials must, therefore, have a low friction coefficient and high wear resistance.…”